KRTL Holding Group Reports Strong Financial Results
Lakewood, CO — KRTL Holding Group Inc. (OTC: KRTL) recently unveiled its financial results for the third quarter of 2025, showcasing an exciting period of growth and development. The company also announced the successful completion of a PCAOB audit for its financial statements for the years ended December 31, 2024, and 2023, reinforcing its commitment to transparency and accountability.
CEO Highlights Successful PCAOB Audit
Cesar Herrera, Chief Executive Officer, expressed enthusiasm about the PCAOB-audited financial statements, noting that they matched previous unaudited reports with no discrepancies. The recent quarterly results, covering three and nine-month periods ending September 30, 2025, reflect a significant milestone for the company due to the incorporation of its newly acquired subsidiary, Industria Químico Farmacéutica Sigma Corp. S.R.L. ('Sigma').
New Subsidiary Contributes to Revenue Growth
The revenue generated from Sigma’s operations over the 28 days since its acquisition was $1,752,656 for the quarter. Overall, KRTL reported total revenues of $1,815,781, demonstrating solid performance during a transitionary phase. This acquisition is pivotal as it offers KRTL a scalable revenue base while preparing for expansion into pharmaceutical and nutraceutical markets, particularly with a view towards opportunities in the U.S. marketplace.
Strong Performance Metrics from Sigma
Independently, Sigma achieved approximately $19.7 million in revenue for the six months leading to September 30, 2025, with an impressive gross margin of 57%. This signifies an annualized revenue run rate of around $40 million based solely on this half-year data. Notably, Sigma's manufacturing facility is currently operating at merely 40% capacity, suggesting that it can potentially support annual revenues near $100 million without increasing fixed costs significantly.
Positive Outlook for Future Growth
As of September 30, 2025, KRTL stands strong with approximately $23.8 million in total assets and $8.7 million in shareholders' equity. Herrera pointed out that completing the PCAOB audit is a key step in advancing towards the company’s goal of uplisting to a higher-tier trading venue. This uplisting could enhance visibility and trading liquidity, making KRTL more appealing to institutional investors who may have restrictions against lower-tier market investments.
Plans for Uplisting and Market Expansion
With PCAOB audited financials now finalized, the company plans to actively pursue an uplisting, contingent on meeting necessary requirements and favorable market conditions. Management is confident that this strategic move will broaden the investor base and facilitate greater funding opportunities to drive growth.
Distribution Channels and International Reach
KRTL's strategic focus on expanding its distribution of healthcare products across multiple international markets, particularly in the United States, is integral to its growth strategy. Through leveraging synergies across its subsidiaries, including KRTL Biotech, Inc and KRTL International Corp, the company aims to enhance its offerings and deliver greater shareholder value.
Investor Communication and Resources
The public is encouraged to review KRTL's recently uploaded Quarterly Report, along with the PCAOB-audited financial statements from the previous two years available on OTC Markets. These documents provide additional insights into the company's financial health and operational strategies.
About KRTL Holding Group
KRTL Holding Group, Inc. operates through its subsidiaries, emphasizing growth through strategic initiatives in biotech and technology. The blend of these sectors not only bolsters revenue potential but also enriches the firm's commitment to delivering value to its investors.
Frequently Asked Questions
What financial results did KRTL report for Q3 2025?
KRTL reported a total revenue of $1,815,781 for the three months ended September 30, 2025.
How did the acquisition of Sigma impact KRTL’s revenue?
Sigma contributed $1,752,656 to KRTL's revenues during its initial 28 days of operations, enhancing the overall revenue performance.
What is KRTL's plan for uplisting?
KRTL intends to pursue uplisting to a higher-tier market to enhance visibility and attract institutional investors, pending satisfaction of listing requirements.
What are Sigma's financial performance metrics?
Sigma generated approximately $19.7 million in revenue for the six months ending September 30, 2025, achieving a gross margin of 57%.
How can investors stay informed about KRTL's activities?
Investors can review the Quarterly Report and PCAOB-audited financial statements available on OTC Markets for detailed financial information.
